scispace - formally typeset
Open AccessJournal ArticleDOI

The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol

Simon Shorvon, +1 more
- 01 Oct 2011 - 
- Vol. 134, Iss: 10, pp 2802-2818
Reads0
Chats0
TLDR
There is an urgent need for the establishment of a database of outcomes of individual therapies for super-refractory status epilepticus, which is an uncommon but important clinical problem with high mortality and morbidity rates.
Abstract
Super-refractory status epilepticus is defined as status epilepticus that continues or recurs 24 h or more after the onset of anaesthetic therapy, including those cases where status epilepticus recurs on the reduction or withdrawal of anaesthesia. It is an uncommon but important clinical problem with high mortality and morbidity rates. This article reviews the treatment approaches. There are no controlled or randomized studies, and so therapy has to be based on clinical reports and opinion. The published world literature on the following treatments was critically evaluated: anaesthetic agents, anti-epileptic drugs, magnesium infusion, pyridoxine, steroids and immunotherapy, ketogenic diet, hypothermia, emergency resective neurosurgery and multiple subpial transection, transcranial magnetic stimulation, vagal nerve stimulation, deep brain stimulation, electroconvulsive therapy, drainage of the cerebrospinal fluid and other older drug therapies. The importance of treating the identifying cause is stressed. A protocol and flowchart for managing super-refractory status epilepticus is suggested. In view of the small number of published reports, there is an urgent need for the establishment of a database of outcomes of individual therapies.

read more

Citations
More filters
Journal ArticleDOI

Antagomirs targeting microRNA-134 increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced status epilepticus

TL;DR: In vivo evidence that microRNA-134 regulates spine volume in the hippocampus is provided and validation of the seizure-suppressive effects of miR-134 antagomirs in a model with a different triggering mechanism is validated, indicating broad conservation of anticonvulsant effects.
Journal ArticleDOI

Refractory and super‐refractory status epilepticus in adults: a 9‐year cohort study

TL;DR: This work describes RSE and SRSE frequencies and identifies associated clinical variables in status epilepticus continuing after general anaesthesia and describes the prevalence and related clinical profiles of these patients.
Journal ArticleDOI

Incidence and mortality of super-refractory status epilepticus in adults

TL;DR: The mortality of patients with SRSE, 36%, was comparable to earlier studies and twofold higher than the mortality of Patients with RSE, and approximately 20% of patients treated in Finnish ICUs progressed to having SRSE.
Journal ArticleDOI

Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application

TL;DR: Accumulating evidence in animal models highlights that inflammation ensuing in the brain during SE may play a determinant role in ongoing seizures and their long-term detrimental consequences, independent of an infection or auto-immune cause.
References
More filters
Journal ArticleDOI

Magnesium gates glutamate-activated channels in mouse central neurones

TL;DR: The voltage dependence of the NMDA receptor-linked conductance appears to be a consequence of the voltage dependenceof the Mg2+ block and its interpretation does not require the implication of an intramembrane voltage-dependent ‘gate’.
Journal ArticleDOI

Refractory Status Epilepticus: Frequency, Risk Factors, and Impact on Outcome

TL;DR: Refractory status epilepticus occurs in approximately 30% of patients with SE and is associated with increased hospital length of stay and functional disability, and nonconvulsive SE and focal motor seizures at onset are risk factors for RSE.

The treatment of convulsive status epilepticus, recommendations of the epilepsy foundation of america’s working group on status epilepticus

TL;DR: Common to all patients is the need for a clear plan, prompt administration of appropriate drugs in adequate doses, and attention to the possibility of apnea, hypoventilation, or other metabolic abnormalities.
Related Papers (5)